AVONEX^® (interferon beta-1a) Clinical Benefits

• AVONEX is the only MS therapy proven effective after the first attack, to reduce flare-ups and slow physical disability*
• Reduce the number of flare-ups
  • In a 3-year study of people who had only one flare-up, AVONEX reduced the risk of a second flare-up by almost half (44%)
  • In people who had multiple (9 or more) brain lesions, AVONEX reduced their risk of having a second flare-up by 66%, at 3 years
  • At 10 years the risk of a second flare-up was reduced by 40% in people who began AVONEX therapy immediately compared with those who delayed therapy
• Slow down physical disability
  • AVONEX slowed down physical disability by 37% in a 2-year study
  • In a separate study, 90% of people taking AVONEX stayed below an EDSS of 3.0 at 5 years, which means they were still active and able after 5 years
  • 80% of people taking AVONEX stayed below an EDSS of 3.0 at 10 years, which means they were still active and able at 10 years



• Reduce brain lesions and the rate of brain shrinkage^†
  • AVONEX slows down the formation of harmful brain lesions and reduces the size of lesions by 91%
  • In the second year of a clinical trial, people taking AVONEX had 55% less brain shrinkage than those not on therapy

AVONEX has been proven effective in clinical trials for up to 3 years.

To learn more, visit avonex.com

*People with MS in whom effectiveness has been demonstrated include people who have experienced a first attack and have lesions consistent with MS on their MRI.

^†Though studies suggest there is an impact, the exact relationship between MRI findings and your overall health is not fully understood.

This information is not intended to replace discussions with a healthcare provider.

Please see full AVONEX Luer Lock Prefilled Syringe Prescribing Information and AVONEX Medication Guide.

Please see full AVONEX Powdered Form Prescribing Information and AVONEX Medication Guide.